Safety of Nivestim® in Patients Treated With Neutropenia-inducing Anticancer Chemotherapy in Routine Practice

Trial Profile

Safety of Nivestim® in Patients Treated With Neutropenia-inducing Anticancer Chemotherapy in Routine Practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Filgrastim (Primary) ; Filgrastim (Primary)
  • Indications Febrile neutropenia
  • Focus Adverse reactions
  • Acronyms NEXT
  • Sponsors Hospira
  • Most Recent Events

    • 12 Dec 2015 Results of sub-group analysis (n=463) presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
    • 14 Jun 2015 Results (subanalysis) presented at the 20th Congress of the European Haematology Association (n = 455).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top